Cargando…

Emerging treatment options for patients with high-risk myelodysplastic syndrome

Myelodysplastic syndromes (MDS) are clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis with peripheral blood cytopenias, dysplastic cell morphology, and a variable risk of progression to acute myeloid leukemia (AML). The hypomethylating agents (HMA) azacitidine and d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bewersdorf, Jan Philipp, Carraway, Hetty, Prebet, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7675905/ https://www.ncbi.nlm.nih.gov/pubmed/33240476 http://dx.doi.org/10.1177/2040620720955006

Ejemplares similares

Clinical Management of Anemia in Patients with Myelodysplastic Syndromes: An Update on Emerging Therapeutic Options
por: Lewis, Russell, et al.
Publicado: (2021)

Risk-Adapted, Individualized Treatment Strategies of Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
por: Bewersdorf, Jan Philipp, et al.
Publicado: (2021)

Lower‐risk myelodysplastic syndromes: Current treatment options for anemia
por: Meunier, Mathieu, et al.
Publicado: (2022)

Beyond Ruxolitinib: Fedratinib and Other Emergent Treatment Options for Myelofibrosis
por: Bewersdorf, Jan Philipp, et al.
Publicado: (2019)

Current challenges and unmet medical needs in myelodysplastic syndromes
por: Platzbecker, Uwe, et al.
Publicado: (2021)

Treatment options for lower-risk myelodysplastic syndromes. Where are we now?
por: Volpe, Virginia O., et al.
Publicado: (2021)

Inherited Thrombocytopenia Caused by Germline ANKRD26 Mutation Should Be Considered in Young Patients With Suspected Myelodysplastic Syndrome
por: Kewan, Tariq, et al.
Publicado: (2020)

Emerging therapies for acute myeloid leukemia
por: Saygin, Caner, et al.
Publicado: (2017)

Patterns of Diagnostic Evaluation and Determinants of Treatment in Older Patients With Non-transfusion Dependent Myelodysplastic Syndromes
por: Mukherjee, Sudipto, et al.
Publicado: (2023)

Molecular Targeted Therapy in Myelodysplastic Syndromes: New Options for Tailored Treatments
por: Pagliuca, Simona, et al.
Publicado: (2021)

Molecular features of early onset adult myelodysplastic syndrome
por: Hirsch, Cassandra M., et al.
Publicado: (2017)

Use of immunosuppressive therapy for management of myelodysplastic syndromes: a systematic review and meta-analysis
por: Stahl, Maximilian, et al.
Publicado: (2020)

Facing the challenge: Novel treatment options for patients with myelodysplastic syndromes
por: Kubasch, Anne Sophie, et al.
Publicado: (2018)

Setting Fire to ESA and EMA Resistance: New Targeted Treatment Options in Lower Risk Myelodysplastic Syndromes
por: Kubasch, Anne Sophie, et al.
Publicado: (2019)

A phase I/II multicenter, open-label, dose escalation and randomized trial of BI 836858 in patients with low- or intermediate-1-risk myelodysplastic syndrome
por: Komrokji, Rami S., et al.
Publicado: (2022)

Emerging Therapies for the Myelodysplastic Syndromes
por: Canaani, Jonathan
Publicado: (2019)

Epigenetic therapy combinations in acute myeloid leukemia: what are the options?
por: Bewersdorf, Jan Philipp, et al.
Publicado: (2019)

Emerging treatments for myelodysplastic syndromes: Biological rationales and clinical translation
por: Rodriguez-Sevilla, Juan Jose, et al.
Publicado: (2023)

Myelodysplastic syndrome patient-derived xenografts: from no options to many
por: Côme, Christophe, et al.
Publicado: (2020)

New targets for therapy in breast cancer: Mammalian target of rapamycin (mTOR) antagonists
por: Carraway, Hetty, et al.
Publicado: (2004)

Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome
por: DiNardo, Courtney D., et al.
Publicado: (2022)

PB2014: A PHASE 2/3 TRIAL OF ORAL AZACITIDINE IN PATIENTS WITH LOW- OR INTERMEDIATE-RISK MYELODYSPLASTIC SYNDROMES
por: Garcia-Manero, Guillermo, et al.
Publicado: (2023)

Decitabine in the treatment of myelodysplastic syndromes
por: Saba, Hussain I
Publicado: (2007)

Management of patients with lower-risk myelodysplastic syndromes
por: Brunner, Andrew M., et al.
Publicado: (2022)

Emerging Insights into Molecular Mechanisms of Inflammation in Myelodysplastic Syndromes
por: Vallelonga, Veronica, et al.
Publicado: (2023)

New Treatments for Myelodysplastic Syndromes
por: D’Alò, Francesco, et al.
Publicado: (2010)

Part 5: Myelodysplastic syndromes—Treatment of high-risk disease
por: Magalhães, Silvia Maria Meira, et al.
Publicado: (2018)

Azacytidine (Vidaza®) in the treatment of myelodysplastic syndromes
por: Raj, Kavita, et al.
Publicado: (2006)

Insights into novel emerging epigenetic drugs in myeloid malignancies
por: Chandhok, Namrata S., et al.
Publicado: (2019)

Outcome of patients treated for myelodysplastic syndromes without deletion 5q after failure of lenalidomide therapy
por: Prebet, Thomas, et al.
Publicado: (2017)

Molecular Pathogenesis and Treatment of Myelodysplastic Syndromes
por: Nakajima, Hideaki
Publicado: (2020)

Emerging pharmacologic treatment options for fragile X syndrome
por: Schaefer, Tori L, et al.
Publicado: (2015)

Treatment options for hypertension in high-risk patients
por: Tsai, Wei-Chuan
Publicado: (2011)

Signal transduction inhibitors in treatment of myelodysplastic syndromes
por: Bachegowda, Lohith, et al.
Publicado: (2013)

Clinical utility of lenalidomide in the treatment of myelodysplastic syndromes
por: Abou Zahr, Abdallah, et al.
Publicado: (2014)

PB2020: OUTCOMES OF PATIENTS WITH HIGH RISK MYELODYSPLASTIC SYNDROMES
por: Amor, Imen Ben, et al.
Publicado: (2023)

Understanding the Continuum between High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia
por: Zavras, Phaedon D., et al.
Publicado: (2023)

Safety and efficacy of azacitidine in the treatment of elderly patients with myelodysplastic syndrome
por: Ritchie, Ellen K
Publicado: (2012)

Myelodysplastic Syndromes and Metabolism
por: Balaian, Ekaterina, et al.
Publicado: (2021)

Genetics of Myelodysplastic Syndromes
por: Saygin, Caner, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_sssj6jijn4bf5pq6ppl5sa0mee